



Sandro Anchisi

Kontakt

Sandro Anchisi

Publikationen (5)

Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlmann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. *Swiss Med Wkly* 2021; 151:w20464.

Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlmann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). *BMC cancer* 2021; 21:182.

Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribi K, Thürlmann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). *J Bone Oncol* 2019; 21:100273.

Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. *BMC cancer* 2016; 16:780.

Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). *Eur J Cancer* 2011; 48:377-84.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch